Skip to main content
PMC home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 1994;15(4):417–431. doi: 10.1007/BF01837368

Therapeutic uses of recombinant complement protein inhibitors

Kimberly R Kalli 1, Peihong Hsu 2, Douglas T Fearon 1,2
PMCID: PMC7101590  PMID: 8153875

Conclusion

In conclusion, it is apparent that researchers are poised at the threshold of developing inhibitors of complement activation from the molecules in the RCA family. By creating soluble forms of these protective proteins for in vivo administration, or by making transgenic animals expressing these proteins or their derivatives, it may be possible to inhibit complement-mediated pathology stemming from autoimmune disease, reperfusion injuries, and physical trauma. This technology combined with current attempts to protect allografts from cellular rejection with monoclonal antibodies against members of the integrin family of adhesion molecules [52] makes it possible that the excessive mortality due to the severe shortage of human donor organs could be overcome by the use of xenografts.

Keywords: Autoimmune Disease, Integrin, Adhesion Molecule, Reperfusion Injury, Soluble Form

References

  • 1.Abrahamson DR, Fearon DT. Endocytosis of the C3b receptor of complement within coated pits in human polymorphonuclear leukocytes and monocytes. Lab Invest. 1983;48:162. [PubMed] [Google Scholar]
  • 2.Adams EM, Brown MC, Nunge M, Krych M, Atkinson JP. Contribution of the repeating domains of membrane cofactor protein (CD46) of the complement system to ligand binding and cofactor activity. J Immunol. 1991;147:3005. [PubMed] [Google Scholar]
  • 3.Ahearn JM, Fearon DT. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21) Adv Immunol. 1989;46:183. doi: 10.1016/s0065-2776(08)60654-9. [DOI] [PubMed] [Google Scholar]
  • 4.Alsenz J, Lambris JD, Schulz TF, Dierich MP. Localization of the complement-component-C3b-binding site and the cofactor activity for factor I in the 38-kDa tryptic fragment of factor H. Biochem J. 1984;224:389. doi: 10.1042/bj2240389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Alsenz J, Schulz TF, Lambris JD, Sim RB, Dierich MP. Structural and functional analysis of the complement component factor H with the use of different enzymes and monoclonal antibodies to factor H. Biochem J. 1985;232:841. doi: 10.1042/bj2320841. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Atkinson JP, Farries T. Separation of self from non-self in the complement system. Immunol Today. 1987;8:212. doi: 10.1016/0167-5699(87)90167-8. [DOI] [PubMed] [Google Scholar]
  • 7.Auchincloss H., Jr Xenogeneic transplantation. A review. Transplantation. 1988;46:1. doi: 10.1097/00007890-198807000-00001. [DOI] [PubMed] [Google Scholar]
  • 8.Bach FH. Discordant xenografting: a summary and look to the future. Trans Proc. 1992;24:739. [PubMed] [Google Scholar]
  • 9.Bach FH, Turman MA, Vercellotti GM, Platt JL, Dalmasso AP. Accommodation: a working paradigm for progressing toward clinical discordant xenografting. Trans Proc. 1991;23:205. [PubMed] [Google Scholar]
  • 10.Baker PJ, Osofsky SG. Activation of human complement by heat-killed, human kidney cells grown in cell culture. J Immunol. 1980;124:81. [PubMed] [Google Scholar]
  • 11.Bischoff SC, De Weck AL, Dahinden CA. Interleukin 3 and granulocyte/macrophage-colony-stimulating factor render human basophils responsive to low concentrations of complement component C3a. Proc Natl Acad Sci USA. 1990;87:6813. doi: 10.1073/pnas.87.17.6813. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Bora NS, Lublin DM, Kumar BV, Hockett RD, Holers VM, Atkinson JP. Structural gene for human membrane cofactor protein (MCP) of complement maps to within 100 kb of the 3′ end of the C3b/C4b receptor gene. J Exp Med. 1989;169:597. doi: 10.1084/jem.169.2.597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Calne RY. Organ transplantation between widely disparate species. Trans Proc. 1970;2:550. [PubMed] [Google Scholar]
  • 14.Campbell RD, Law SKA, Reid KBM, Sim RB. Structure, organization and regulation of the complement genes. Annu Rev Immunol. 1988;6:161. doi: 10.1146/annurev.iy.06.040188.001113. [DOI] [PubMed] [Google Scholar]
  • 15.Carel J-C, Myones BL, Frazier B, Holers VM. Structural requirements for C3d,g/ Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection. J Biol Chem. 1990;265:12293. [PubMed] [Google Scholar]
  • 16.Carroll MC, Aliquot EM, Katzman PJ, Klickstein LB, Smith JA, Fearon DT. Organization of the genes encoding complement receptors type 1 and 2, decay-accelerating factor, and C4-binding protein in the RCA locus on human chromosome 1. J Exp Med. 1988;167:1271. doi: 10.1084/jem.167.4.1271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Carter RH, Spycher MO, Ng YC, Hoffman R, Fearon DT. Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes. J Immunol. 1988;141:457. [PubMed] [Google Scholar]
  • 18.Cochrane CG (984) The role of complement in experimental disease models. Springer Semin Immunopathol 7:263 [DOI] [PubMed]
  • 19.Cochrane CG, Müller-Eberhard HJ, Aikin BS. Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J Immunol. 1970;105:55. [PubMed] [Google Scholar]
  • 20.Couser WG, Baker PJ, Adlers S. Complement and the direct mediation of immune glomerular injury: a new perspective. Kidney Int. 1985;28:879. doi: 10.1038/ki.1985.214. [DOI] [PubMed] [Google Scholar]
  • 21.Cornacoff JB, Hebert LA, Smead WL, Van Aman ME, Birmingham DJ, Waxman FJ. Primate-erythrocyte immune complex-clearing mechanism. J Clin Invest. 1983;71:236. doi: 10.1172/JCI110764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Coyne KE, Hall SE, Thompson ES, Arce MA, Kinoshita T, Fujita T, Anstee DJ, Rosse W, Lublin DM. Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay acceleration factor. J Immunol. 1993;149:2906. [PubMed] [Google Scholar]
  • 23.Crawford MH, Grover FL, Kolb WP, McMahon CA, O'Rourke RA, McManus LM, Pinckard RN. Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury. Circulation. 1988;78:1449. doi: 10.1161/01.cir.78.6.1449. [DOI] [PubMed] [Google Scholar]
  • 24.Daha MR, Bloem AC, Ballieux RE. Immunoglobulin production by human peripheral lymphocytes induced by anti-C3 receptor antibodies. J Immunol. 1984;132:1197. [PubMed] [Google Scholar]
  • 25.Dalmasso AP, Vercellotti GM, Platt JL, Bach FH. Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor. Potential for prevention of xenograft hyperacute rejection. Transplantation. 1991;52:530. doi: 10.1097/00007890-199109000-00029. [DOI] [PubMed] [Google Scholar]
  • 26.Dykman TR, Cole JL, Iida K, Atkinson JP. Polymorphism of human erythrocyte C3b/C4b receptor. Proc Natl Acad Sci USA. 1983;80:1698. doi: 10.1073/pnas.80.6.1698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Dykman TR, Cole JL, Iida K, Atkinson JP. Structural heterogeneity of the C3b/C4b receptor (CR1) on human peripheral blood cells. J Exp Med. 1983;157:2160. doi: 10.1084/jem.157.6.2160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Dykman TR, Hatch JA, Atkinson JP. Polymorphism of the human C3b/C4b receptor. Identification of a third allele and analysis of receptor phenotypes in families and patients with systemic lupus erythematosus. J Exp Med. 1984;159:691. doi: 10.1084/jem.159.3.691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Dykman TR, Hatch JA, Aqua MS, Atkinson JP. Polymorphism of the C3b/C4b receptor (CR1): characterization of a fourth allele. J Immunol. 1985;134:1787. [PubMed] [Google Scholar]
  • 30.Fearon DT. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc Natl Acad Sci USA. 1979;76:5867. doi: 10.1073/pnas.76.11.5867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Fearon DT. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J Exp Med. 1980;152:20. doi: 10.1084/jem.152.1.20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Feasby TE, Gilbert JJ, Hahn AF, Neilson M. Complement depletion suppresses Lewis rat experimental allergic neuritis. Brain Res. 1987;419:97. doi: 10.1016/0006-8993(87)90572-5. [DOI] [PubMed] [Google Scholar]
  • 33.Fischel RJ, Bolman RM, III, Platt JL, Naharian KS, Bach FH, Matas AJ. Removal of IgM anti-endothelial antibodies results in prolonged cardiac xenograft survival. Trans Proc. 1990;22:1077. [PubMed] [Google Scholar]
  • 34.Forty J, Hasan R, Cary N, White DJG, Wallwork J. Hyperacute rejection of rabbit hearts by human blood is mediated by the alternative pathway of complement. Trans Proc. 1992;24:488. [PubMed] [Google Scholar]
  • 35.Fujita T, Gigli I, Nussenzweig V. Human C4-binding protein. II. Role in proteolysis of C4b by C3b-inactivator. J Exp Med. 1978;148:1044. doi: 10.1084/jem.148.4.1044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Fujita T, Inoue T, Ogawa K, Iida K, Tamura N. The mechanism of action of decay-accelerating factor (DAF) J Exp Med. 1987;166:1221. doi: 10.1084/jem.166.5.1221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Garcia-Estan J, Roman RJ, Lianos EA, Garancis J. Effects of complement depletion on glomerular eicosanoid production and renal hemodynamics in rat nephrotoxic serum nephritis. J Lab Clin Med. 1989;114:389. [PubMed] [Google Scholar]
  • 38.Gelfand MC, Frank MM, Green I. A receptor for the third component of complement in the human renal glomerulus. J Exp Med. 1975;142:1029. doi: 10.1084/jem.142.4.1029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Gelfand JA, Donelan M, Hawiger A, Burke JF. Alternative complement pathway activation increases mortality in a model of burn injury in mice. J Clin Invest. 1982;70:1170. doi: 10.1172/JCI110715. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Gigli I, Fearon DT. Regulation of the classical pathway convertase of human complement by the C3b receptor from human erythrocytes (abstract) Fed Proc. 1981;40:1172. [Google Scholar]
  • 41.Gigli I, Fujita T, Nussenzweig V. Modulation of the classical pathway C3 convertase by plasma proteins C4-binding protein and C3b inactivator. Proc Natl Acad Sci USA. 1979;76:6596. doi: 10.1073/pnas.76.12.6596. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Hamilton KH, Hattori R, Esmon CT, Sims PJ. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem. 1990;265:3809. [PubMed] [Google Scholar]
  • 43.Hebell T, Ahearn JM, Fearon DT. Suppression of the immune response by a soluble complement receptor of B lymphocytes. Science. 1991;254:102. doi: 10.1126/science.1718035. [DOI] [PubMed] [Google Scholar]
  • 44.Heyman B, Wiersma EJ, Kinoshita T. In vivo inhibition of the antibody response by a complement receptor-specific monoclonal antibody. J Exp Med. 1990;172:665. doi: 10.1084/jem.172.2.665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Heideman M. Complement activation in vitro induced by endotoxin and injured tissue. J Surg Res. 1979;26:670. doi: 10.1016/0022-4804(79)90063-5. [DOI] [PubMed] [Google Scholar]
  • 45a.Hill J, Lindsay TF, Ortiz F, Yeh CG, Hechtman HB, Moore FD., Jr Soluble complement receptor type I ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat. J Immunol. 1992;149:1723. [PubMed] [Google Scholar]
  • 46.Hinglais N, Kazatchkine MD, Mandet C, Appay MD, Bariety J. Human liver Kupffer cells express CR1, CR3, and CR4 complement receptor antigens. An immunohistochemical study. Lab Invest. 1989;61:509. [PubMed] [Google Scholar]
  • 47.Holguin MH, Martin CB, Bernshaw NJ, Parker CJ. Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with a isolated deficiency of decay accelerating factor. J Immunol. 1992;148:498. [PubMed] [Google Scholar]
  • 48.Hourcade D, Miesner DR, Atkinson JP, Holers VM. Identification of an alternative polyadenylation site in the human C3b/C4b receptor (complement receptor type 1) transcriptional unit and prediction of a secreted form of complement receptor type 1. J Exp Med. 1988;168:1255. doi: 10.1084/jem.168.4.1255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Hourcade D, Holers VM, Atkinson JP. The regulators of complement activation (RCA) gene cluster. Adv Immunol. 1989;45:381. doi: 10.1016/s0065-2776(08)60697-5. [DOI] [PubMed] [Google Scholar]
  • 50.Hourcade D, Miesner DR, Bee C, Zeldes W, Atkinson JP. Duplication and divergence of the amino-terminal coding region of the complement receptor 1 (CR1) gene. An example of concerted (horizontal) evolution within a gene. J Biol Chem. 1990;265:974. [PubMed] [Google Scholar]
  • 51.Iida K, Nussenzweig V. Complement receptor is an inhibitor of the complement cascade. J Exp Med. 1981;153:1138. doi: 10.1084/jem.153.5.1138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Isobe M, Yagita H, Okumura K, Ihara A. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science. 1992;255:1125. doi: 10.1126/science.1347662. [DOI] [PubMed] [Google Scholar]
  • 53.Janatova J, Reid KBM, Willis AC (1986) Involvement of disulfide bonds in the structure of complement regulatory protein C4bp. FASEB J 2: 8922A
  • 54.Kalli KR, Ahearn JM, Fearon DT. Interaction of iC3b with recombinant isotypic and chimeric forms of CR2. J Immunol. 1991;147:590. [PubMed] [Google Scholar]
  • 55.Kalli KR, Hsu P, Bartow TJ, Ahearn JA, Matsumoto AK, Klickstein LB, Fearon DT. Mapping of the C3b-binding site in CR1 and construction of a chimeric (CR1)2-F(ab′)2 complement inhibitor. J Exp Med. 1991;174:1451. doi: 10.1084/jem.174.6.1451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Kazatchkine MD, Fearon DT, Appay MD, Mandet C, Bariety J. Immunohistochemical study of the human glomerular C3b receptor in normal kidney and in seventy-five cases of renal diseases. J Clin Invest. 1982;69:900. doi: 10.1172/JCI110529. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Klickstein LB, Wong WW, Smith JA, Weis JH, Wilson JG, Fearon DT. Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristic of C3/C4 binding proteins. J Exp Med. 1987;165:1095. doi: 10.1084/jem.165.4.1095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Klickstein LB, Bartow TJ, Miletic V, Rabson LD, Smith JA, Fearon DT. Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis. J Exp Med. 1988;168:1699. doi: 10.1084/jem.168.5.1699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Krych M, Hourcade D, Atkinson JP. Sites within the complement C3b/C4b receptor important for the specificity of ligand binding. Proc Natl Acad Sci USA. 1991;88:4353. doi: 10.1073/pnas.88.10.4353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Kurimoto Y, De Weck AL, Dahinden CA. Interleukin 3-dependent mediator release in basophils triggered by C5a. J Exp Med. 1989;170:467. doi: 10.1084/jem.170.2.467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Lennon VA, Seybold ME, Lindstrom JM, Cochrane C, Ulevitch R. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J Exp Med. 1978;147:973. doi: 10.1084/jem.147.4.973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Liszewski MK, Post TW, Atkinson JP. Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu Rev Immunol. 1991;9:431. doi: 10.1146/annurev.iy.09.040191.002243. [DOI] [PubMed] [Google Scholar]
  • 63.Lowell CA, Klickstein LB, Carter RH, Mitchell JA, Fearon DT, Ahearn JA. Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2. J Exp Med. 1989;170:1931. doi: 10.1084/jem.170.6.1931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Lozier J, Takahashi N, Putnam FW. Complete amino acid sequence of human plasma β2-glycoprotein I. Proc Natl Acad Sci USA. 1984;81:3640. doi: 10.1073/pnas.81.12.3640. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Lublin DM, Atkinson JP. Decay-accelerating factor and membrane cofactor protein. Curr Top Microbiol Immunol. 1989;153:124. doi: 10.1007/978-3-642-74977-3_7. [DOI] [PubMed] [Google Scholar]
  • 66.Lublin DM, Lemons RS, LeBeau MM, Holers VM, Tykocinski ML, Medof ME, Atkinson JP. The gene encoding decay-accelerating factor (DAF) is located in the complementregulatory locus on the long arm of chromosome 1. J Exp Med. 1987;165:1731. doi: 10.1084/jem.165.6.1731. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Maroko PR, Carpenter CB, Chiariello M, Fishbein MC, Radvany P, Knostman JD, Hale SL. Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion. J Clin Invest. 1978;61:661. doi: 10.1172/JCI108978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Matsumoto AK, Kopicky-Burd J, Carter RH, Tuveson DA, Tedder TF, Fearon DT. Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19. J Exp Med. 1991;173:55. doi: 10.1084/jem.173.1.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Medof ME, Nussenzweig V. Control of the function of substrate-bound C4b-C3b by the complement receptor CR1. J Exp Med. 1984;159:1669. doi: 10.1084/jem.159.6.1669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Medof ME, Iida K, Mold C, Nussenzweig V. Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes. J Exp Med. 1982;156:1739. doi: 10.1084/jem.156.6.1739. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Medof ME, Kinoshita T, Silber R, Nussenzweig V. Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor. Proc Natl Acad Sci USA. 1985;82:2980. doi: 10.1073/pnas.82.9.2980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Medof ME, Walter EI, Rutgers JL, Knowles DM, Nussenzweig V. Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med. 1987;165:848. doi: 10.1084/jem.165.3.848. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Merry AH, Rawlinson VI, Uchikawa M, Daha MR, Sim RB. Studies on the sensitivity to complement-mediated lysis of erythrocytes (Inab phenotype) with a deficiency of DAF (deca-accelerating factor) Br J Haematol. 1989;73:248. doi: 10.1111/j.1365-2141.1989.tb00260.x. [DOI] [PubMed] [Google Scholar]
  • 74.Mitomo K, Fujita T, Iida K. Functional and antigenic properties of complement receptor type 2, CR2. J Exp Med. 1987;165:1424. doi: 10.1084/jem.165.5.1424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Miyagawa S, Hirose H, Shirakura R, Naka Y, Nakata S, Kawashima Y, Seya T, Matsumoto M, Uenaka A, Kitamura H. The mechanism of discordant xenograft rejection. Transplantation. 1988;46:825. doi: 10.1097/00007890-198812000-00007. [DOI] [PubMed] [Google Scholar]
  • 76.Müller-Eberhard HJ. Molecular organization and function of the complement system. Annu Rev Biochem. 1988;57:321. doi: 10.1146/annurev.bi.57.070188.001541. [DOI] [PubMed] [Google Scholar]
  • 77.Mulligan MS, Yeh CG, Rudolph AR, Ward PA. Protective effects of soluble CR1 in complement-and neutrophil-mediated tissue injury. J Immunol. 1992;148:1479. [PubMed] [Google Scholar]
  • 78.Ninomiya H, Abe T, Fugita T. Prolongation of red-cell life-span by incorporation of decay-accelerating factor (DAF) into red cells of paroxysmal nocturnal haemoglobinuria (PNH) (letter) Br J Haematol. 1989;73:132. doi: 10.1111/j.1365-2141.1989.tb00234.x. [DOI] [PubMed] [Google Scholar]
  • 79.Nose M, Katoh M, Okata N, Kyogoku M, Okada H. Tissue distribution of HRF20, a novel factor preventing the membrane attack of homologous complement, and its predominant expression on endothelial cells in vivo. Immunology. 1990;70:145. [PMC free article] [PubMed] [Google Scholar]
  • 80.Ogata RT, Mathias P, Bradt B, Cooper NR. SCRs 1–3 of murine C4b-binding protein (C4-bp) are required for binding to C4b (abstract) Complement Inflamm. 1991;8:202. [Google Scholar]
  • 81.Oglesby TJ, White D, Tedja I, Liszewski MK, Wright L, van den Bogarde J, Atkinson J. Protection of mammalian cells from complement-mediated lysis by transfection of human membrane cofactor protein and decay-accelerating factor. Trans Assoc Am Phys. 1991;104:164. [PubMed] [Google Scholar]
  • 82.Oglesby TJ, Allen CJ, Liszewski MK, White DJG, Atkinson JP. Membrane cofactor protein (CD46) protects cells from complement-mediated attack by an intrinsic mechanism. J Exp Med. 1992;175:1547. doi: 10.1084/jem.175.6.1547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Pangburn MK. Reduced activity of DAF on complement enzymes bound to alternative pathway activators. Similarity with Factor H. Immunology. 1990;71:598. [PMC free article] [PubMed] [Google Scholar]
  • 84.Pangburn MK, Müller-Eberhard HJ. The alternative pathway of complement. Spring Semin Immunopathol. 1984;7:163. doi: 10.1007/BF01893019. [DOI] [PubMed] [Google Scholar]
  • 85.Platt JL, Vercellotti GM, Dalmasso AP, Matas AJ, Bolman RM, Najarian JS, Bach FH. Transplantation of discordant xenografts: a review of progress. Immunol Today. 1990;11:450. doi: 10.1016/0167-5699(90)90174-8. [DOI] [PubMed] [Google Scholar]
  • 86.Platt JL, Vercellotti GM, Lindman BJ, Oegema TR, Jr, Bach FH, Dalmasso AP. Release of heparin sulfate from endothelial cells. Implications for pathogenesis of hyper-acute rejection. J Exp Med. 1990;171:1363. doi: 10.1084/jem.171.4.1363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Platt JL, Fischel RJ, Matas AJ, Reif SA, Bolman RM, Bach FH. Immunopathology of hyperacute xenograft refection in a swine-to-primate model. Transplantation. 191;52:214. doi: 10.1097/00007890-199108000-00006. [DOI] [PubMed] [Google Scholar]
  • 88.Pruitt SK, Bollinger RR. The effect of soluble complement receptor type 1 on hyperacute allograft rejection. J Surg Res. 1991;50:350. doi: 10.1016/0022-4804(91)90202-w. [DOI] [PubMed] [Google Scholar]
  • 89.Pruitt SK, Baldwin WM, III, Marsh HC, Jr, Lin SS, Yeh CG, Bollinger RR. The effect of soluble complement receptor type 1 on hyperacute xenograft rejection. Transplantation. 1991;52:868. doi: 10.1097/00007890-199111000-00022. [DOI] [PubMed] [Google Scholar]
  • 90.Pruitt SK, Baldwin WM, III, Marsh HC, Jr, Lin SS, Yeh CG, Bollinger RR. Effect of soluble complement receptor type 1 on natural antibody levels during xenograft rejection. Trans Proc. 1992;24:477. [PubMed] [Google Scholar]
  • 91.Quigg RJ, Cybulsky AV, Salant DJ. Effect of nephritogenic antibody on complement regulation in cultured rat glomerular epithelial cells. J Immunol. 1991;147:838. [PubMed] [Google Scholar]
  • 92.Reid KBM, Day AJ. Structure-function relationships of the complement components. Immunol Today. 1989;10:177. doi: 10.1016/0167-5699(89)90317-4. [DOI] [PubMed] [Google Scholar]
  • 93.Rey-Campos J, Rubenstein P, de Rodriguez Cordoba S. A physical map of the human regulator of complement activation gene cluster linking the complement genes CR1, CR2, DAF, and C4BP. J Exp Med. 1988;167:664. doi: 10.1084/jem.167.2.664. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.Reynes M, Aubert JP, Cohen JHM, Audouin J, Tricottet V, Diebold J, Kazatchkine MD. Human follicular dendritic cells express CR1, CR2 and CR3 complement receptor antigens. J Immunol. 1985;135:2687. [PubMed] [Google Scholar]
  • 95.de Rodriguez Cordoba S, Dykman TR, Ginsberg-Fellner F, Ercilla G, Aqua M, Atkinson JP, Rubinstein P. Evidence for linkage between the loci encoding for the binding protein for the fourth component of human complement (C4BP) and for the C3b/C4b receptor. Proc Natl Acad Sci USA. 1984;81:789. doi: 10.1073/pnas.81.24.7890. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.de Rodriguez Cordoba S, Lublin DM, Rubenstein P, Atkinson JP. Human genes for three complement components that regulate the activation of C3 are tightly linked. J Exp Med. 1985;161:1189. doi: 10.1084/jem.161.5.1189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Ross GD, Lambris JD, Cain JA, Newman SL. Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 activity. J Immunol. 1982;129:2051. [PubMed] [Google Scholar]
  • 98.Scharfstein J, Ferreira A, Gigli I, Nussenzweig V. Human C4-binding protein. I. Isolation and characterization. J Exp Med. 1978;148:207. doi: 10.1084/jem.148.1.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Seya T, Atkinson JP. Functional properties of membrane cofactor protein of complement. Biochem J. 1989;264:581. doi: 10.1042/bj2640581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.Solomkin JS, Cotta LA, Satoh PS, Hurst JM, Nelson RD. Complement activation and clearance in acute illness and injury: evidence for C5a as a cell-directed mediator of the adult respiratory distress syndrome in man. Surgery. 1985;97:668. [PubMed] [Google Scholar]
  • 101.Tate CG, Uchikawa M, Tanner MJ, Judson PA, Parsons SF, Mallinson G, Anstee DJ. Studies on the defect which causes absence of decay-accelerating factor (DAF) from the peripheral blood cells of an individual with the Inab phenotype. Biochem J. 1989;1261:489. doi: 10.1042/bj2610489. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 102.Tuveson DA, Ahearn JM, Matsumoto AK, Fearon DT. Molecular interactions of complement receptors on B lymphocytes: a CR1/CR2 complex distinct from the CR2/CD19 complex. J Exp Med. 1991;173:1083. doi: 10.1084/jem.173.5.1083. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Wang M-W, Wright LJ, Sims MJ, White DJG. Presence of human chromosome 1 with expression of human decay-accelerating factor (DAF) prevents lysis of mouse/human hybrid cells by human complement. Scand J Immunol. 1991;34:771. doi: 10.1111/j.1365-3083.1991.tb01602.x. [DOI] [PubMed] [Google Scholar]
  • 104.Wang M-W, Johnston PS, Wright LJ, Lim SML, White DJG. Immunofluorescent localization of pig complement component 3, regardless of the presence or absence of detectable immunoglobulins, in hyperacutely rejected heart xenografts. Histochem J. 1992;24:102. doi: 10.1007/BF01082446. [DOI] [PubMed] [Google Scholar]
  • 105.Watson WC, Townes AS. Genetic susceptibility to murine collagen II autoimmune arthritis. Proposed relationship to the IgG2 autoantibody subclass response, complement C5, major histocompatibility complex (MHC) and non-HMC loci. J Exp Med. 1985;162:1878. doi: 10.1084/jem.162.6.1878. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106.Weis JH, Morton CC, Bruns GAP, Weis JJ, Klickstein LB, Wong WW, Fearon DT. A complement receptor locus: genes encoding C3b/C4b receptor and C3d/Epstein-Barr virus receptor map to 1q32. J Immunol. 1987;138:312. [PubMed] [Google Scholar]
  • 107.Weisman HF, Bartow T, Leppo MK, Marsh HC, Jr, Carson GR, Concino MF, Boyle MP, Roux KH, Weisfeldt ML, Fearon DT. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Sciecne. 1990;249:146. doi: 10.1126/science.2371562. [DOI] [PubMed] [Google Scholar]
  • 108.Weiss L, Delfraissy J-F, Vazquez A, Wallon C, Galanaud P, Kazatchkine MD. Monoclonal antibodies to the human C3b/C4b receptor (CR1) enhance specific B cell differentiation. J Immunol. 1987;138:2988. [PubMed] [Google Scholar]
  • 109.Whaley K, Ruddy S. Modulation of the alternative complement pathway by β1H globulin. J Exp Med. 1976;144:1147. doi: 10.1084/jem.144.5.1147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 110.White DJG, Oglesby T, Liszewski MK, Tedja I, Hourcade D, Wang M-W, Wright L, Wallwork J, Atkinson JP. Expression of human decay-accelerating factor or membrane cofactor protein genes on mouse cells inhibits lysis by human complement. Trans Proc. 1992;24:474. [PubMed] [Google Scholar]
  • 111.Wilson JG, Tedder TF, Fearon DT. Characterization of human T lymphocytes that express the C3b receptor. J Immunol. 1983;131:684. [PubMed] [Google Scholar]
  • 112.Wong WW, Farrell SA. Proposed structure of the F′ allotype of human CR1. Loss of a C3b binding site may be associated with altered function. J Immunol. 1991;146:656. [PubMed] [Google Scholar]
  • 113.Wong WW, Wilson JG, Fearon DT. Genetic regulation of a structural polymorphism of human C3b receptor. J Clin Invest. 1983;72:685. doi: 10.1172/JCI111018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114.Wong WW, Kennedy CA, Bonaccio ET, Wilson JG, Klickstein LB, Weis JH, Fearon DT. Analysis of multiple restriction fragment length polymorphisms of the gene for the human complement receptor type 1. Duplication of genomic sequences occurs in association with a high molecular mass receptor allotype. J Exp Med. 1986;164:1531. doi: 10.1084/jem.164.5.1531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 115.Wong WW, Cahill JM, Rosen MD, Kennedy CA, Bonaccio ET, Morris MJ, Wilson JG, Klickstein LB, Fearon DT. Structure of the human CR1 gene. Molecular basis of the structural and quantitative polymorphisms and identification of a new CR1-like allele. J Exp Med. 1989;169:847. doi: 10.1084/jem.169.3.847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 116.Vedeler CA, Nilsen R, Matre R. Localization of Fc receptors and complement receptors CR1 on human peripheral nerve fibers by immunoelectron microscopy. J Neuroimmunol. 1989;23:29. doi: 10.1016/0165-5728(89)90069-6. [DOI] [PubMed] [Google Scholar]
  • 117.Xia W, Fearon DT, Moore FD, Jr, Schoen FJ, Ortiz F, Kirkman RL. Prolongation of guinea pig cardiac xenograft survival in rats by soluble human complement receptor type 1. Trans Proc. 1992;24:479. [PubMed] [Google Scholar]
  • 118.Yang Q-E, Want YY, Bollinger RR, De Buysscher EV. Discordant complement systems as a factor in hyperacute xenograft rejection. Trans Proc. 1992;24:481. [PubMed] [Google Scholar]
  • 119.Yeh GC, Marsh HC, Jr, Carson GR, Berman L, Concino MF, Scesney SM, Kuestner RE, Skibbens R, Donahue KA, Ip SH. Recombinant soluble human complement receptor type 1 inhibits inflammation in the reversed passive arthus reaction in rats. J Immunol. 1991;146:250. [PubMed] [Google Scholar]

Articles from Springer Seminars in Immunopathology are provided here courtesy of Nature Publishing Group

RESOURCES